[go: up one dir, main page]

SMT202100343T1 - Metodi per aumenare l'inibizione tonica e trattare la sindrome di angelman - Google Patents

Metodi per aumenare l'inibizione tonica e trattare la sindrome di angelman

Info

Publication number
SMT202100343T1
SMT202100343T1 SM20210343T SMT202100343T SMT202100343T1 SM T202100343 T1 SMT202100343 T1 SM T202100343T1 SM 20210343 T SM20210343 T SM 20210343T SM T202100343 T SMT202100343 T SM T202100343T SM T202100343 T1 SMT202100343 T1 SM T202100343T1
Authority
SM
San Marino
Prior art keywords
methods
angelman syndrome
tonic inhibition
treating angelman
increasing tonic
Prior art date
Application number
SM20210343T
Other languages
English (en)
Inventor
Matthew During
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of SMT202100343T1 publication Critical patent/SMT202100343T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
SM20210343T 2014-06-06 2015-06-03 Metodi per aumenare l'inibizione tonica e trattare la sindrome di angelman SMT202100343T1 (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462008939P 2014-06-06 2014-06-06
EP18169211.2A EP3372229B1 (en) 2014-06-06 2015-06-03 Methods of increasing tonic inhibition and treating angelman syndrome

Publications (1)

Publication Number Publication Date
SMT202100343T1 true SMT202100343T1 (it) 2021-07-12

Family

ID=54767324

Family Applications (2)

Application Number Title Priority Date Filing Date
SM20210340T SMT202100340T1 (it) 2014-06-06 2015-06-03 Metodi per aumentare l'inibizione tonica e trattare l'insonnia secondaria
SM20210343T SMT202100343T1 (it) 2014-06-06 2015-06-03 Metodi per aumenare l'inibizione tonica e trattare la sindrome di angelman

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM20210340T SMT202100340T1 (it) 2014-06-06 2015-06-03 Metodi per aumentare l'inibizione tonica e trattare l'insonnia secondaria

Country Status (20)

Country Link
US (11) US20150352085A1 (it)
EP (3) EP3795156A1 (it)
JP (4) JP2017516868A (it)
AR (1) AR100772A1 (it)
AU (4) AU2015269667B2 (it)
CA (1) CA2950845C (it)
CY (2) CY1124366T1 (it)
DK (2) DK3372229T3 (it)
ES (2) ES2876350T3 (it)
HR (2) HRP20210901T1 (it)
HU (2) HUE055400T2 (it)
IL (2) IL249287B (it)
LT (2) LT3372229T (it)
MX (2) MX391502B (it)
PL (2) PL3372229T3 (it)
PT (2) PT3372229T (it)
RS (2) RS62007B1 (it)
SI (2) SI3151832T1 (it)
SM (2) SMT202100340T1 (it)
WO (1) WO2015187851A1 (it)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100340T1 (it) 2014-06-06 2021-07-12 Ovid Therapeutics Inc Metodi per aumentare l'inibizione tonica e trattare l'insonnia secondaria
US10434308B2 (en) 2015-05-29 2019-10-08 Medtronic, Inc. Impedance matching and electrode conditioning in patient interface systems
US10080898B2 (en) 2015-05-29 2018-09-25 Medtronic, Inc. Simultaneous physiological sensing and stimulation with saturation detection
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
EP4541420A3 (en) * 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
WO2018017639A1 (en) * 2016-07-19 2018-01-25 Georgia State University Research Foundation Methods for treating rett syndrome
JP2019524816A (ja) * 2016-08-11 2019-09-05 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． てんかん性障害の処置のための方法および組成物
AU2017363598A1 (en) * 2016-11-22 2019-05-23 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
KR20200047557A (ko) 2017-08-04 2020-05-07 오비드 테라퓨틱스 인크. 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용
US11181384B2 (en) * 2018-07-23 2021-11-23 Waymo Llc Verifying map data using challenge questions
CA3113644A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
JP2022514194A (ja) * 2018-11-21 2022-02-10 セルテゴ セラピューティクス インコーポレイテッド 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
MX2021007224A (es) 2018-12-17 2021-09-23 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
EP3982937A4 (en) * 2019-07-15 2022-08-10 Ovid Therapeutics Inc. PHARMACEUTICAL FORMULATIONS WITH GABOXADOL FOR THERAPEUTIC TREATMENT
CN114786669A (zh) * 2019-12-18 2022-07-22 奥维德医疗公司 用于1p36缺失综合征的治疗性治疗的加波沙朵
EP4153549A2 (en) 2020-05-20 2023-03-29 Certego Therapeutics Inc. Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
JP7600661B2 (ja) * 2020-12-11 2024-12-17 ａｒｔｉｅｎｃｅ株式会社 貼付剤

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
US20080269278A1 (en) 2004-04-02 2008-10-30 H. Lundbeck A/S Treatment of Impaired Respiratory Function with Gaboxadol
DE102005020882A1 (de) * 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
US20090143335A1 (en) 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol
CA2705733C (en) 2007-11-13 2015-02-03 Cadence Pharmaceuticals Reduced dose intravenous acetaminophen
EP2334299A1 (en) * 2008-09-01 2011-06-22 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat
SMT202100340T1 (it) * 2014-06-06 2021-07-12 Ovid Therapeutics Inc Metodi per aumentare l'inibizione tonica e trattare l'insonnia secondaria
EP4541420A3 (en) * 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment

Also Published As

Publication number Publication date
US20250025448A1 (en) 2025-01-23
MX2016016136A (es) 2017-07-05
HRP20210901T1 (hr) 2021-09-17
AU2020217342A1 (en) 2020-08-27
EP3372229B1 (en) 2021-03-24
US20160038469A1 (en) 2016-02-11
US20170071917A1 (en) 2017-03-16
LT3151832T (lt) 2021-07-12
AU2015269667B2 (en) 2020-07-30
MX380868B (es) 2025-03-12
LT3372229T (lt) 2021-07-12
IL249287B (en) 2021-03-25
EP3151832A4 (en) 2018-01-17
RS62007B1 (sr) 2021-07-30
US9339495B2 (en) 2016-05-17
AU2022200085A1 (en) 2022-02-03
JP2021178836A (ja) 2021-11-18
SI3372229T1 (sl) 2021-09-30
ES2875742T3 (es) 2021-11-11
US20160228418A1 (en) 2016-08-11
PL3151832T3 (pl) 2021-10-25
HUE055400T2 (hu) 2021-11-29
EP3151832B1 (en) 2021-03-24
US9744159B2 (en) 2017-08-29
AU2015269667A1 (en) 2016-12-22
US9446028B2 (en) 2016-09-20
SMT202100340T1 (it) 2021-07-12
JP2020063264A (ja) 2020-04-23
WO2015187851A1 (en) 2015-12-10
PL3372229T3 (pl) 2021-10-04
MX391502B (es) 2025-03-21
HUE055155T2 (hu) 2021-11-29
IL268960A (en) 2019-10-31
IL268960B (en) 2021-05-31
CA2950845A1 (en) 2015-12-10
US20170087133A1 (en) 2017-03-30
US11278529B2 (en) 2022-03-22
AU2024202604A1 (en) 2024-05-09
US20150352085A1 (en) 2015-12-10
US20220016091A1 (en) 2022-01-20
PT3372229T (pt) 2021-06-17
EP3795156A1 (en) 2021-03-24
JP2023123442A (ja) 2023-09-05
JP2017516868A (ja) 2017-06-22
DK3151832T3 (da) 2021-06-14
PT3151832T (pt) 2021-06-15
AR100772A1 (es) 2016-11-02
MX2020012404A (es) 2022-04-11
CA2950845C (en) 2023-04-25
EP3151832A1 (en) 2017-04-12
ES2876350T3 (es) 2021-11-12
EP3372229A1 (en) 2018-09-12
CY1124368T1 (el) 2022-07-22
US20180303805A1 (en) 2018-10-25
US20170273956A1 (en) 2017-09-28
IL249287A0 (en) 2017-02-28
AU2020217342B2 (en) 2021-10-07
RS62006B1 (sr) 2021-07-30
US9801864B2 (en) 2017-10-31
DK3372229T3 (da) 2021-06-14
US20230051859A1 (en) 2023-02-16
CY1124366T1 (el) 2022-07-22
US20180015076A1 (en) 2018-01-18
SI3151832T1 (sl) 2021-08-31
HRP20210902T1 (hr) 2021-09-17

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
PL3372229T3 (pl) Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana
ZA202006746B (en) Methods of treatment
IL258768A (en) Compounds interacting with glycans and methods of use
IL250415B (en) Antibodies against pd-l and methods of using them
IL259801A (en) ezh2 inhibitors and methods of using them
IL273932A (en) Methods of treatment and prevention of viral infection
IL282482A (en) Variants of protoxin-II and methods of use
ZA201706257B (en) Treatment of wood
GB201709038D0 (en) Security devices and methods of manufacture thereof
GB201514760D0 (en) Compounds and method of use
IL282508A (en) Variants of protoxin-II and methods of use
PL3183003T3 (pl) SPOSOBY ZAPOBIEGANIA l/LUB LECZENIA ZAKAŻENIA
GB201520900D0 (en) Devices and methods for treatment of ventilator associated dysphagia
IL254825A0 (en) Methods of treatment with Tesalisib
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
PT3397364T (pt) Elementos estruturados e métodos de utilização
GB201416832D0 (en) Methods of treatment
GB201413530D0 (en) Treatment and prevention of malaria
GB201511799D0 (en) Composition and methods of treatment
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
IL252779B (en) Prevention and treatment of inflammatory diseases
HUE058190T2 (hu) Enoláz inhibitorok és ezekkel történõ kezelési eljárások
GB201417248D0 (en) Compostion and methods of treatment
GB201512139D0 (en) Methods of treatment